Treeway: Pioneering the biggest genetic research project in Amyotrophic Lateral Sclerosis




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Treeway: Pioneering the biggest genetic research project in Amyotrophic Lateral Sclerosis
Released on: May 16, 2016. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Following his own diagnosis with ALS in 2010, oil and shipping entrepreneur Bernard Muller co-founded Treeway, a biotechnology company with a mission to develop therapies to treat and cure the disease.
  • Summary
  • Transcript
  • Participants
  • Company
Following his own diagnosis with ALS in 2010, oil and shipping entrepreneur Bernard Muller co-founded Treeway, a biotechnology company with a mission to develop therapies to treat and cure the disease. Bernard discusses his criteria for entrepreneurship, and how he has turned a personal fight into the world's biggest genetic research project into ALS.
Following his own diagnosis with ALS in 2010, oil and shipping entrepreneur Bernard Muller co-founded Treeway, a biotechnology company with a mission to develop therapies to treat and cure the disease. Bernard discusses his criteria for entrepreneurship, and how he has turned a personal fight into the world's biggest genetic research project into ALS.
A serial entrepreneur within the maritime & oil industry. He has introduced new business models in the largest port of Europe, for which he was awarded by the port of Rotterdam and in 2013 his company received the gold “gazelle” for fastest growing company in Holland. Bernard has been confronted in June 2010 with adversity being diagnosed with ALS and since then has initiated the world-largest genetic research project for ALS, called project MinE and founded Treeway.
Treeway
Treeway is a biotechnology company with a mission to develop therapies to cure ALS. It was founded in 2012 by two ALS patients. It has established strong patient empowerment within the target market. Treeway focuses on rational target validation and drug development. The management team has wide expertise in drug development, as well as in leading start-up and established companies. Treeway closely collaborates with (global) research and clinical institutes, and is involved in establishing the grounds for TRICALS, a European institute for performing clinical trials specifically in ALS. Treeway’s two founders are the initiators of Project MinE, the world’s largest research initiative devoted to discovering the genetic cause of ALS. Although Treeway is a start-up company, we have established relationships with ALS researchers and doctors globally. We are a leader within this therapeutic area and are in the process of developing a robust pipeline. Our vision Today’s world is characterized by instant access to information and almost unlimited interconnectivity. Because of this we envision patients to play leading roles in the quest for cures. Patients, scientists, and industry will join forces to translate discoveries into therapeutics while minimizing time to market, in both rare and common diseases. Our mission The name Treeway stems from the words tree of life and pathway of a disease, for the founders a symbolic way towards a cure. It is our mission to eradicate ALS from the face of the earth. We strive to accomplish this by speeding up ALS research in collaboration with academic- and research centers around the globe. We aim to have new therapies on the market as soon as possible. Everyone can make a difference and our mantra “one man can and will find a way, why not be that man…” underpins our drive and strive to inspire others.